BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX · NASDAQ Global Select
+$0.09 today
Vol 7.30M · Avg 4.85M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $172.4M |
| Short-term Investments | $66.8M |
| Receivables | $109.3M |
| Inventory | $6.0M |
| Other Current | $19.1M |
| Total Current Assets | $373.6M |
| PP&E (Net) | $23.0M |
| Long-term Investments | $21.5M |
| Other Non-current | $46.9M |
| Total Non-current Assets | $91.4M |
| Total Assets | $465.1M |
Analysis
Selected assets total $465.1M for Latest. The largest visible component is Cash & Equivalents at $172.4M, about 37.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $89.7M -14.5% | $104.9M -5.2% | $110.6M -63.7% | $304.8M -39.6% | $504.4M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $185.0M -14.4% | $216.1M -22.3% | $278.3M +132.8% | $119.5M +3621.8% | $3.2M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $106.8M +35.1% | $79.1M +38.8% | $57.0M +12.6% | $50.6M +72.0% | $29.4M | $533.8M | $399.4M | -$1.7B |
| Inventory | $5.4M -33.3% | $8.1M -71.8% | $28.7M +4.2% | $27.5M +74.4% | $15.8M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $17.4M +26.4% | $13.8M -35.6% | $21.3M +51.8% | $14.1M +320.3% | $3.3M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $404.3M -4.2% | $422.0M -14.9% | $496.0M -4.0% | $516.5M -8.8% | $566.1M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $19.0M -4.0% | $19.8M -5.4% | $20.9M +142.7% | $8.6M -43.3% | $15.2M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $61.2M +181.6% | $21.7M | $0 -100.0% | $18.1M +164.7% | $6.8M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $29.7M +10.1% | $26.9M +33580.0% | $80.0K -98.8% | $6.8M | $0 | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $109.8M +60.4% | $68.5M +226.1% | $21.0M -37.3% | $33.5M +52.2% | $22.0M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $514.2M +4.8% | $490.4M -5.1% | $517.0M -6.0% | $550.0M -6.5% | $588.2M | $13.3B | $11.9B | $10.6B |
| Account Payables | $15.8M +35.9% | $11.6M -44.3% | $20.9M +45.5% | $14.4M -48.4% | $27.8M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 -100.0% | $35.4M | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 -100.0% | $410.0K -84.4% | $2.6M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 -100.0% | $1.2M -13.9% | $1.4M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $129.7M +100.6% | $64.7M -25.3% | $86.6M +137.5% | $36.5M -29.9% | $52.0M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $196.1M +22.2% | $160.4M +6.9% | $150.0M +42.1% | $105.5M +1.7% | $103.7M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $427.2M -46.3% | $795.9M -1.9% | $811.3M +10.6% | $733.3M +25.2% | $585.5M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $437.2M -45.7% | $806.0M -2.0% | $822.5M +11.3% | $739.1M +25.0% | $591.4M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $633.3M -34.5% | $966.4M -0.6% | $972.5M +15.1% | $844.6M +21.5% | $695.1M | $14.7B | $3.7B | $9.6B |
| Common Stock | $2.1M +2.2% | $2.1M +1.3% | $2.1M +9.5% | $1.9M +2.0% | $1.8M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.5B +14.9% | -$1.8B -5.3% | -$1.7B -15.6% | -$1.5B -20.5% | -$1.2B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $38.0K -95.9% | $921.0K -31.1% | $1.3M +5042.3% | $26.0K -85.3% | $177.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | -$119.2M +75.0% | -$475.9M -4.5% | -$455.5M -54.6% | -$294.6M -175.4% | -$107.0M | $9.1B | $7.7B | $3.3B |
| Total Debt | $438.9M -47.8% | $841.4M +2.0% | $825.1M +11.3% | $741.5M +25.0% | $593.2M | $724.2M | $410.6M | $399.4M |
| Net Debt | $349.1M -52.6% | $736.5M +3.1% | $714.5M +63.6% | $436.7M +391.5% | $88.8M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.32B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.38B
Pharvaris N.V.
NASDAQ:PHVS
$2.29B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.87B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.71B
Zymeworks Inc.
NASDAQ:ZYME
$1.67B
Ardelyx, Inc.
NASDAQ:ARDX
$1.44B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.39B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.16B
Upstream Bio, Inc.
NASDAQ:UPB
$338.75M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does BCRX have?
BioCryst Pharmaceuticals, Inc. (BCRX) reported $89.74M in cash and equivalents in fiscal 2025.
How much debt does BCRX carry?
BioCryst Pharmaceuticals, Inc. (BCRX) reported $438.87M of total debt, with net debt of $349.14M.
Explore More
Continue the stock analysis
Jump to another research area for this company.